z-logo
open-access-imgOpen Access
Could Dietary Glutamate Play a Role in Psychiatric Distress?
Author(s) -
A. Zarina Kraal,
Nicole R. Arvanitis,
Andrew P. Jaeger,
Vicki L. Ellingrod
Publication year - 2019
Publication title -
neuropsychobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.71
H-Index - 83
eISSN - 1423-0224
pISSN - 0302-282X
DOI - 10.1159/000496294
Subject(s) - glutamate receptor , distress , psychiatry , schizophrenia (object oriented programming) , pathophysiology , neurotransmitter , monosodium glutamate , ingestion , psychology , medicine , chronic pain , somatic cell , neuroscience , clinical psychology , central nervous system , biology , genetics , receptor , gene
Glutamate is an amino acid that functions as an excitatory neurotransmitter. It has also been associated with somatic and psychiatric distress and is implicated in the pathophysiology of psychiatric disorders such as schizophrenia. Ingestion of dietary glutamate, such as monosodium glutamate (MSG), has been mechanistically linked with greater distress among patients with chronic pain conditions, though findings have been equivocal. Preliminary research suggests that an MSG-restricted diet confers beneficial effects on somatic symptoms and well-being for some individuals with chronic pain conditions. In addition to associations with somatic distress, glutamate has been associated with the onset and progression of psychiatric symptoms. Thus, the role of dietary glutamate in psychiatric distress represents an underdeveloped and potentially important area for future research aimed at clarifying pathophysiological mechanisms and identifying targets for dietary intervention in psychiatric illnesses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom